Hengrui Pharmaceutical (600276.SH): SHR-1316 (sc) injection obtained drug clinical trial approval notice

Zhitongcaijing · 05/09 10:01

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Suzhou Shengdia Biomedical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-1316 (sc) injections and will conduct clinical trials in the near future. Specifically, this is an open, multicenter phase I clinical study on pharmacokinetics, safety, tolerability and efficacy of SHR-1316 (sc) combined with carboplatin and etoposide in first-line treatment of broad-stage small cell lung cancer.